Squarepoint’s Nuvectis Pharma NVCT Stock Holding History

Squarepoint’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11,012	Closed	-$108K	–	4877
2025 Q1	$108K	Sell	11,012 -8,059	-42%	-$58K	﹤0.01%	4199
2024 Q4	$103K	Buy	+19,071	New	+$119K	﹤0.01%	4689

Other funds holding NVCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

JMFC

J.M. Forbes & Co Boston, Massachusetts $1.27B AUM 26.46% 1-Year Est. Return

Squarepoint's NVCT Position: Q2 2025 in Review

Squarepoint sold out of Nuvectis Pharma (NVCT) in Q2 2025, closing a stake of 11,012 shares — an estimated $108K sold.

Squarepoint first reported a position in NVCT in Q4 2024 and held it in 2 quarters. The position peaked at $108K in Q1 2025. 47 funds tracked by Wall St. Rank hold NVCT as of Q2 2025.

Squarepoint reported no remaining Nuvectis Pharma position as of Q2 2025 after selling out during the quarter.
Squarepoint sold 11,012 Nuvectis Pharma shares in Q2 2025, an estimated $108K.
Squarepoint first reported a position in Nuvectis Pharma in Q4 2024 and held it in 2 quarters.
Squarepoint's Nuvectis Pharma position peaked at $108K in Q1 2025.
47 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.